Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
Non-muscle Invasive Bladder Cancer
BIOLOGICAL: CG0070
Incidence of Treatment-Emergent Adverse Events, Adverse events Grade 3 or higher will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., Up to 2 years
Complete Response Rate (CR), CR as defined by the response assessment., 12 weeks|12-month recurrence free survival rate (RFS), RFS is defined as the time from surgical removal of residual lesions after CG0070 treatment to recurrence of low- or high-grade urothelial carcinoma within the bladder., 12 months|24-month recurrence free survival rate (RFS), RFS is defined as the time from surgical removal of residual lesions after CG0070 treatment to recurrence of low- or high-grade urothelial carcinoma within the bladder., 24 months|Progression free survival (PFS), PFS is defined as the time from documentation of Complete Response (CR) following CG0070 treatment to recurrence of low- or high-grade urothelial carcinoma within the bladder., Up to 24 months|Cystectomy free survival (CFS), CFS is defined as the time from study registration to cystectomy performed for any cause. Reason for cystectomy will be collected and analyzed in conjunction with this endpoint., Up to 24 months
Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).